<code id='EF50323F64'></code><style id='EF50323F64'></style>
    • <acronym id='EF50323F64'></acronym>
      <center id='EF50323F64'><center id='EF50323F64'><tfoot id='EF50323F64'></tfoot></center><abbr id='EF50323F64'><dir id='EF50323F64'><tfoot id='EF50323F64'></tfoot><noframes id='EF50323F64'>

    • <optgroup id='EF50323F64'><strike id='EF50323F64'><sup id='EF50323F64'></sup></strike><code id='EF50323F64'></code></optgroup>
        1. <b id='EF50323F64'><label id='EF50323F64'><select id='EF50323F64'><dt id='EF50323F64'><span id='EF50323F64'></span></dt></select></label></b><u id='EF50323F64'></u>
          <i id='EF50323F64'><strike id='EF50323F64'><tt id='EF50323F64'><pre id='EF50323F64'></pre></tt></strike></i>

          knowledge

          knowledge

          author:hotspot    Page View:14
          The FDA building -- First Opinion coverage from STAT
          Adobe

          The Food and Drug Administration on Thursday approved the first medicine developed specifically to treat the serious liver disease known as MASH.

          The pill, called Rezdiffra, is made by Madrigal Pharmaceuticals.

          advertisement

          Metabolic dysfunction-associated steatohepatitis, or MASH, is often associated with obesity. The accumulation of fat in the liver causes inflammation, which leads to fibrosis, or liver scarring, and can progress in more advanced stages to cirrhosis, cancer, and the need for a liver transplant.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Wikipedia

          Alkermes shareholders re
          Alkermes shareholders re

          MarkLennihan/APAlkermesshareholdersvotedThursdaytore-electallofthedrugmaker’scurrentdirectors,ending

          read more
          Merck to acquire Harpoon Therapeutics for $680 million
          Merck to acquire Harpoon Therapeutics for $680 million

          MelEvans/APMerckannouncedMondayitwillacquireHarpoonTherapeuticsanditspipelineofimmune-basedcancerdru

          read more
          Activists slam private health insurers over coverage restrictions
          Activists slam private health insurers over coverage restrictions

          ProtestorsoutsideAmerica'sHealthInsurancePlansheadquarters.CourtesyPeople'sActionWASHINGTON—Hun

          read more

          JPM 2024 Review: Hope for the XBI, deals from J&J, Merck, GSK

          InhonorofJPMWeek,you’rereadingaspecialeditionofourbiotechnewsletter,TheReadout.Tostayontopofthelates